Human Capital CXO
Intellectual Property

IP & Patent Notice

Human Capital Value (HCV) Model — E(RVBER)

Patent Pending

A U.S. Provisional Patent Application covering the Human Capital Value (HCV) Model, its lifecycle valuation extensions, its deal-level liability adjustment module, and its individual/team/workforce population-scope architecture was filed with the United States Patent and Trademark Office (USPTO) on August 21, 2026, establishing a priority filing date. A corresponding non-provisional (utility) application must be filed within twelve (12) months of that date to preserve priority.
IPC Class: G06Q 10/06

Application Details
Filing Type
Provisional Patent Application (USPTO) — filed
Filing Date
August 21, 2026
Application No.
64/137,976
IPC Class
G06Q 10/06 — Human Resource Management Systems
Inventor
Andreas C. Keller, Neuenhof (AG), Switzerland
Origin
MBA Thesis (Distinction), University of Strathclyde, Glasgow, UK, 2004
Title
Computer-Implemented System and Method for Quantifying Human Capital Monetary Value at Individual, Team, and Workforce Levels Using Dual Control Factor and Deal-Level Liability Adjustments, and Lifecycle Valuation Extensions
Applicant / Assignee
Human Capital CXO, Inc.
What Is Protected

The provisional patent application covers the HCV Model as a computer-implemented system and method that computes the Expected Realizable Value of Balanced Employee Relations [E(RVBER)] — a single monetary present-value figure representing the full economic worth of an employee to an organisation.

The invention's novel contribution is a dual control factor architecture applied to the Flamholtz (1971) stochastic reward baseline, together with a set of lifecycle valuation extensions and a complementary deal-level liability adjustment module. A population-scope architecture makes every valuation method — the core E(RVBER) computation and each lifecycle extension — selectively executable at an individual, team, or workforce level, via employee-level aggregation, weighted population parameters, or probability-weighted cohort computation. The full technical specification, including the underlying formulas and claims, is confidential pending grant and is not published on this page.

Fields of Application

The invention is applicable across the following domains:

HR Accounting & Analytics M&A Due Diligence Organisational Strategic Planning ERP / SAP Integration HR Information Systems (HRIS) Human Capital Reporting Employee Retention Risk Individual, Team & Workforce Valuation
Verifiable Status — What You Can Confirm Now
Provisional filing
Filed August 21, 2026 with the USPTO. Establishes priority date.
MBA thesis origin
The foundational methodology is drawn from the MBA thesis "Human Resource Due Diligence within the Context of M&A — A Mathematical Valuation Model of HR", awarded Distinction, University of Strathclyde, Glasgow, UK, 2004. Verifiable via University of Strathclyde library records.
Current status
Patent Pending — a provisional application has been filed with the USPTO, establishing a priority filing date of August 21, 2026. No patent has yet been granted; full rights are contingent on filing a non-provisional application within twelve (12) months and successful examination. This page will be updated once any patent is granted.
IPC classification
G06Q 10/06 — Human Resource Management Systems. Searchable in the WIPO IPC database.
Patent Lifecycle Timeline
✓ Aug 21, 2026
Provisional Patent Application — filed with USPTO
Filed August 21, 2026. Establishes a priority date. IPC class G06Q 10/06. Twelve-month window to file a corresponding non-provisional application runs to August 21, 2027.
→ by Aug 21, 2027
Non-Provisional (Utility) Patent Application
Full claims filed. Application enters examination queue. Application number becomes public.
→ later
USPTO Examination
Patent examiner reviews claims against prior art. Office actions and responses exchanged.
→ later
Grant (if approved)
Patent granted, number published, full rights in force. Searchable on patents.google.com and USPTO PATFT.
Important Notice: A U.S. provisional patent application for the HCV/HCL Model was filed with the USPTO on August 21, 2026, establishing a priority filing date and affording twelve (12) months in which to file a corresponding non-provisional application. No patent has yet been granted. Unauthorised commercial reproduction, adaptation, or implementation of the HCV Model, its dual control factor architecture, or its software modules may constitute patent infringement once a patent is granted. This notice will be updated as the application's status changes.
Licensing & Enquiries: For licensing, partnership, or integration enquiries (including ERP / SAP integration or white-label HR analytics deployment), please contact the inventor via office.us@humancapitalcxo.com •  LinkedIn.
Trademarks
Switzerland — registered
“HumanCapital CXO” (combined word and device mark) is registered with the Swiss Federal Institute of Intellectual Property under No. 855036, application No. 14930/2026, filed 31 August 2026, registered 3 September 2026, Nice Classes 035 and 042, protected to 31 August 2036. Proprietor: Andreas C. Keller, Neuenhof (AG), Switzerland. Verifiable at swissreg.ch. The three-month opposition period under Art. 31 MSchG runs from publication.
United States — pending
“HumanCapital CXO”, USPTO Serial No. 50051041, filed 14 August 2026 on the Principal Register, Classes 035 and 042. Pending examination; not registered.
Use of the ® symbol
Where ® appears next to HumanCapital CXO, it refers to Swiss registration No. 855036 and to no other registration. The mark is not registered in the United States, where the application remains pending. Trademark rights are separate from and independent of the patent position set out above.
Licence
The marks stand in the name of Andreas Christian Keller personally and are used by Human Capital CXO, Inc. under licence.
Third-party references and trademarks.
The HCV valuation models are developed and owned by Human Capital CXO, Inc. Where the published work of third-party authors or institutions is cited — including Flamholtz (1971), Likert (1967), Weisbrod (1961), Lev & Schwartz (1971), Jaggi & Lau (1974), Gut-Villa (1997), Fraumeni (2011), the World Economic Forum (2020), Willis Towers Watson (2020) and the McKinsey Global Institute (2022) — such references are made solely for the purpose of academic attribution.

None of these authors or organisations has participated in, reviewed, validated, sponsored, certified or endorsed the HCV models or any HumanCapital CXO® product or service, and no commercial, contractual or institutional affiliation of any kind exists or is implied.

All parameter values, role classifications, weightings and calibrations implemented in the software are those of Human Capital CXO, Inc. All third-party names, marks and logos are the property of their respective owners and are used, where they appear at all, in a purely descriptive and referential manner.